Pharmacodynamic Activity of [ 18 F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2 -Mutated Breast Cancer Receiving Talazoparib.

MLA

Lin, Lilie L., et al. “Pharmacodynamic Activity of [ 18 F]-Fluorthanatrace Poly(ADP-Ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2 -Mutated Breast Cancer Receiving Talazoparib.” JCO Precision Oncology, vol. 8, Aug. 2024, p. e2400303. EBSCOhost, https://doi.org/10.1200/PO.24.00303.

APA

Lin, L. L., Wong, F., Lin, R., Yap, T., & Litton, J. K. (2024). Pharmacodynamic Activity of [ 18 F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2 -Mutated Breast Cancer Receiving Talazoparib. JCO Precision Oncology, 8, e2400303. https://doi.org/10.1200/PO.24.00303

Chicago

Lin, Lilie L, Franklin Wong, Ruitao Lin, Timothy Yap, and Jennifer K Litton. 2024. “Pharmacodynamic Activity of [ 18 F]-Fluorthanatrace Poly(ADP-Ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2 -Mutated Breast Cancer Receiving Talazoparib.” JCO Precision Oncology 8 (August): e2400303. doi:10.1200/PO.24.00303.